Skip to main content

Table 5 Cox regression analyses of progression-free survival in cervical squamous cell carcinoma patients

From: Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma

Factor

PFS

OS

HR

(95%CI)

P-value

HR

(95%CI)

P-value

Age

5.423

(1.113–26.419)

0.036

4.265

(0.901–20.194)

0.067

Family history of cancer

–

–

–

–

History of miscarriage

0.521

(0.150–1.809)

0.304

0.735

(0.208–2.600)

0.634

Tumor size

1.629

(0.443–5.598)

0.463

2.310

(0.571–9.345)

0.240

Tumor type

0.947

(0.400–2.239)

0.901

0.594

(0.194–1.820)

0.362

Histologic grade

0.922

(0.374–2.271)

0.860

0.772

(0.291–2.045)

0.602

FIGO stage

1.031

(0.221–4.804)

0.969

0.934

(0.196–4.450)

0.931

SCC-Ag

0.720

(0.067–7.774)

0.787

0.931

(0.086–10.035)

0.953

CEA

0.766

(0.194–3.015)

0.702

1.902

(0.342–10.581)

0.463

TSGF

0.381

(0.096–1.515)

0.171

0.657

(0.154–2.808)

0.571

Pelvic lymph nodes

5.035

(1.140–22.231)

0.033

2.844

(0.571–14.166)

0.202

HPV E1-specific T cell response

7.252

(1.690–31.126)

0.008

7.499

(1.661–33.856)

0.009

Treatment

1.595

(0.532–4.784)

0.405

0.118

(0.347–3.603)

0.851

  1. FIGO International Federation of Gynecology and Obstetrics, SCC-Ag Squamous cell carcinoma antigen, CEA carcinoembryonic antigen, TSGF Tumor specific growth factor, HPV Human papillomavirus